Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The heads of Germany's Bayer Schering Pharma AG and the Polish biotech firm Bioton, which produces human recombinant insulin, met in the Chinese capital this week to sign an agreement that sets the stage for Bayer to market the biopharmaceutical SciLin across China
You may also be interested in...
Chinese Health Authorities, Alarmed By Prospect Of 100 Million-plus Diabetics, Create Doctor Training Programs As Global Drug Outfits Step Up R&D
BEIJING - Alarmed by a 2010 study that showed China lies at the epicenter of an explosion in new diabetes cases, China's Ministry of Health is stepping up physician training courses and planning screening services across major cities, according to Chinese and Western scholars
Chinese Health Authorities, Alarmed By Prospect Of 100 Million-plus Diabetics, Create Doctor Training Programs As Global Drug Outfits Step Up R&D
BEIJING - Alarmed by a 2010 study that showed China lies at the epicenter of an explosion in new diabetes cases, China's Ministry of Health is stepping up physician training courses and planning screening services across major cities, according to Chinese and Western scholars
China At Ground Zero In Explosion of New Diabetes Cases; International Federation Now Projects 500 Million Diabetics Worldwide By 2030
BEIJING - A vast new study conducted by scientists in North America and Asia places China at ground zero in terms of an explosion in the incidence of diabetes, and "shows that the global burden of diabetes is far larger than previously estimated," according to a scholar at the Brussels, Belgium-based International Diabetes Federation